Genotype and intensive pretreatment influence outcome of acute myeloid leukemia patients treated with venetoclax in combination with hypomethylating agents or low-dose cytarabine: "real world" data from germany

Tools

Preview	PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 554kB
	MS Word (Supplemental Material) 254kB

Item Type:	Letter
Title:	Genotype and intensive pretreatment influence outcome of acute myeloid leukemia patients treated with venetoclax in combination with hypomethylating agents or low-dose cytarabine: "real world" data from germany
Creators Name:	Braitsch, K., Schmalbrock, L.K., Jung, P., Bumeder, I., Kiewe, P., Hecker, J.S., Verbeek, M., Westermann, J., Bullinger, L., Keller, U., Bassermann, F., Krönke, J., Götze, K.S. and Rieger, K.
Source:	HemaSphere
ISSN:	2572-9241
Publisher:	Wolters Kluwer
Volume:	6
Number:	9
Page Range:	e759
Date:	September 2022
Official Publication:	https://doi.org/10.1097/HS9.0000000000000759
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year